{"id":72319,"date":"2025-09-23T12:01:47","date_gmt":"2025-09-23T12:01:47","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/09\/23\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/"},"modified":"2025-09-23T12:01:47","modified_gmt":"2025-09-23T12:01:47","slug":"texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/","title":{"rendered":"Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment"},"content":{"rendered":"<div>\n<p><em>New program delivers TULSA Procedure\u2019s precision treatment &#8211; minimal side effects, no overnight hospital stay \u2013 to Medicare patients across Texas<\/em><\/p>\n<p align=\"justify\">TORONTO, Sept.  23, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rVi7VWdUr9c-MULz1wlgrCQz3EfTD9O00oLQSF09vWPOldjQlwmxGjHzu7eiEVqDwWP_-aomiqIGMBEVkPB1d12Zj19D04Z7bSZuDDeQE4A=\" rel=\"nofollow\" target=\"_blank\" title=\"Profound Medical Corp.\">Profound Medical Corp.<\/a> (NASDAQ:PROF; TSX:PRN) (\u201cProfound\u201d or the \u201cCompany\u201d), a commercial-stage medical device company developing AI-powered, incision-free therapies for ablating diseased tissue, announced today the launch of a first-of-its-kind TULSA program by <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ccz8bRTPBoBFW76ReqCIAQdoCaKa-rPu5AiwbOvhZ29DAsLe5lIn3GsYrzI2TjykZLn9Z_nnWxt67grL3Y-quyele3sWSjH8FrIY-8uQ8BI=\" rel=\"nofollow\" target=\"_blank\" title=\"Texas Prostate\">Texas Prostate<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7XvVdGd1eVz36MJ_a6eB_YgVTMfvtRri1oMvTubDGvxf27brzynB1fU5Y76TeMkzS8n_ETB384G4SfkNlAQsr63pQ8cp7GXgPLleopUuIYU=\" rel=\"nofollow\" target=\"_blank\" title=\"Dallas Medical Center\">Dallas Medical Center<\/a> to meet the growing demand for advanced prostate treatment \u2014 without surgery. Under the program, Texas Prostate will perform TULSA procedures for men with prostate cancer and benign prostatic hyperplasia (\u201cBPH\u201d) in Dallas Medical Center\u2019s state-of-the-art MRI suite, significantly expanding Medicare patient access to the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s9LFd14gsyFfdTNn39bmm4LxrzqKX7_7-nMHmAU_UxOpe3uGlO9fuTq8CWmtNQHOOxn3ChXAsELgkBdZ-ZeNtiyGRIWJpU47ihMVUoldXwE=\" rel=\"nofollow\" target=\"_blank\" title=\"TULSA Procedure\">TULSA Procedure<\/a>\u2122.<\/p>\n<p align=\"justify\">\u201cThe TULSA procedure is integral to our practice because it offers many men effective prostate treatment without the life-altering side effects of surgery \u2014 such as incontinence or erectile dysfunction,\u201d said Dr. James Cochran, founder of Texas Prostate. \u201cWith Medicare coverage now available, we\u2019ve been seeking ways to offer more men access to this transformative technology. Working with Dallas Medical Center allows us to do just that.\u201d<\/p>\n<p align=\"justify\">In January, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dUAeYbwOY9S4B75gHH5RES-BJrn-kQA5vXTog5YeUWEySmTWb-eyyZ8gp56uOORY-1VvRKCq-ZLcCjeOTfq7-4efeZDmjqScRzrcp_M0YgxscRClbmNEIItqCUDDUfvhUMv3NAXllP2wtLxj7s5lQwKcYKiDj5Jue5dC1Er0b67XEfwivTgOStXwEwcP1wdI7gl_i6BXQHNxHN3qtAyLBPdGcvgR71OR13JGc-doKHcu1lelnUpORcW0h_hnjkXSSxYviE5z3nDVduyxSEDX03CTR2uMjhc96WQw-WAysC_6kJurx6rp0s5TS-XaLJOyiwRrT02EMHtX5Hb9fPLCdj__sKDLY5uCbIvM3ieVRxNIAsB7aiKxS3beTQSaO3cz9Wo-FxwXX3tlOzUiaql5z0zuTWvWjtkOcr4BHimhJ2Q=\" rel=\"nofollow\" target=\"_blank\" title=\"2025 Medicare coverage was granted for the TULSA Procedure\">2025 Medicare coverage was granted for the TULSA Procedure<\/a> performed in Hospital Outpatient, Ambulatory Surgical Center and Private Office\/Non-Facility settings, broadening access to the treatment. This collaboration makes the TULSA Procedure available under Medicare coverage, with Texas Prostate now performing TULSA procedures exclusively at Dallas Medical Center. The hospital gains both advanced technology and the Texas Prostate team\u2019s proven expertise in performing TULSA Procedures.<\/p>\n<p align=\"justify\">\u201cAt Dallas Medical Center, we\u2019re committed to bringing advanced, compassionate care to our patients,\u201d said Ruben Garza, CEO of Dallas Medical Center. \u201cBy working with Texas Prostate, patients can be treated with the TULSA-PRO<sup>\u00ae<\/sup> system in our state-of-the-art MRI suite \u2014 and then return home the same day, with no procedural blood loss, and a significantly lower risk of complications.\u201d<\/p>\n<p align=\"justify\">Profound Medical CEO Arun Menawat added, \u201cThe versatility of TULSA enables the treatment of a wide variety of prostate disease including whole gland or targeted gland treatments, and we are thrilled to see that this new program will provide access to a wider population of patients. Importantly, it also provides a model for private pay urology practices and Medicare accepting hospitals nationwide seeking to expand access to the TULSA procedure.\u201d<\/p>\n<p align=\"justify\">The TULSA Procedure represents a major advancement in prostate care. Unlike traditional treatments that involve surgery, radiation, or lengthy recovery times, the TULSA Procedure is performed inside an MRI suite using robotically guided, directional ultrasound to precisely ablate targeted prostate tissue \u2014 without harming surrounding structures<strong>. <\/strong>The TULSA-PRO system \u2014 the technology behind the procedure \u2014 is the only AI-powered, MRI-guided robotic system for prostate treatment. It allows physicians to visualize the prostate in real time and customize therapy for each patient with unmatched precision.<\/p>\n<p align=\"justify\"><strong>About Profound Medical Corp.<\/strong><\/p>\n<p align=\"justify\">Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.<\/p>\n<p align=\"justify\">Profound is commercializing TULSA-PRO<sup>\u00ae<\/sup>, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (\u201cBPH\u201d); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for precision to preserve patients\u2019 urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57\u00b0C. TULSA is an incision- and radiation-free \u201cone-and-done\u201d procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (\u201cFDA\u201d).<\/p>\n<p align=\"justify\">Profound is also commercializing Sonalleve<sup>\u00ae<\/sup>, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.<\/p>\n<p><strong>Forward-Looking Statements<\/strong><\/p>\n<p align=\"justify\">This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, any express or implied statements or guidance regarding current or future financial performance; the expectations regarding the efficacy of Profound\u2019s technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment and osteoid osteoma; and the success of Profound\u2019s U.S. commercialization strategy and activities for TULSA-PRO<sup>\u00ae<\/sup>. Often, but not always, forward-looking statements can be identified by the use of words such as &#8220;plans&#8221;, &#8220;is expected&#8221;, &#8220;expects&#8221;, &#8220;scheduled&#8221;, &#8220;intends&#8221;, &#8220;contemplates&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;proposes&#8221; or variations (including negative variations) of such words and phrases, or state that certain actions, events or results &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;might&#8221; or &#8220;will&#8221; be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Profound, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition, statements and projections regarding financial guidance and goals and the attainment of such goals may differ from actual results based on market factors and Profound\u2019s ability to execute its operational and budget plans; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management&#8217;s expected ranges. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound&#8217;s Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2rwtBlPtUvqF1e8Y1tJRkFlTSMkmkCsFT1qgiIVlHwCvNqUB4_CdXeYltaht9VQr37VaOg7pt6mpS6LPcTxZhYB35IPW3MB4dBVlYKaVFJzxnsAg_vp1pXFXP5N_a9rjGGQ8CA484OdKgR9ANIPVIjvDkAJ-tXHJ0ffCcMKebG49L0ubOOg9Nx5zpjMxiqQgk3edTvaKFcPxKNe02QGFhaIbQ3xqxfFM9xKB1pGhsez9K4p3PFYxk0cMye6cOmsqGmHo_YwIZwfGuq0xy6F8Dg==\" rel=\"nofollow\" target=\"_blank\" title=\"www.sedarplus.ca\">www.sedarplus.ca<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2rwtBlPtUvqF1e8Y1tJRkGImYCjWfAnSNfnDmIfDz6cyvpx9H255IeyveamcZ26syUDMexnnWmSL5eCO5ShXp10U13wAwC5z6Da6ilt1WA4r2SwAPs7NlxkkIe87Kxw_iS04A2SVF_2unmGdGYx3HV2ZgpFuAkLuwKuSuE6szddWkBSFmxmAu8L5Y1h8SCo5Wufk9WvMD-URMg2ep616ibmZ_pUux0t1M0Vs-TSQlbg=\" rel=\"nofollow\" target=\"_blank\" title=\"www.sec.gov\">www.sec.gov<\/a>. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.<\/p>\n<p><strong>For further information, please contact:<\/strong><\/p>\n<p>Stephen Kilmer<br \/>Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yR8TbRbzdYoh5_6qCs1fpif479lGruf7tIW2VmsTgUQWAmi4EYSqk6JgU7FY-sIoc1yqqyLW_Qb0Uxm_EJB7gfL7BKYEdYg45c3imP547SmjYhj7NoqbxGN0_nn4_jqoo_txTCDALugDPU8rmbtG_AZOJ6rQR4sPbRuOBd2N0EYWplE2X8DgIHzhb3u4vBqlgqVgehgCekDchJnpiw2sfuGbMrBNr2ebfy0nkBLErC0JPKAPedFBhRDOpXa0RcPCSh7leRqRb2ZJUhnaUVmzMQ_2zfqRvyWTLsA_vpBOZT2lHe1Z22zP6WFbO44VGS_B\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>skilmer@profoundmedical.com<\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_3SzXNIOLiPUnd2AOHRCTIGVwTiFQ1JbBdwqfM5ybZC-RFGinIhCy4fGQEYKGdDs6T7ZQBr1WReXpYfOn0wxcUKF494ADeAz0G0uxk4GuZj5NYTz8zmaSWsXSEjTLbcAewXDeFGewGZ0u8r6YsPpJYgYITybb1LM4KFMYQmOi6eFsq2GDEFVHhQY16vLUMG9aOBW5OmI5zVKmLeYOntaGprSW21TJU3TJy0zG8VkOcmcFAJVSXlLG65y4r19DsvQswP4m3V2hU6vhls87KyhnA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><br \/><\/a>T: 647.872.4849<\/p>\n<p>Susan Thomas<br \/>Public Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-tDXtj8GXS6glVVSAmci83_JokM5Fi27hvxT5zhYxOjjgrVg70itPuXEv-zRB_3RGzxr4YHD8n4sWiAonw_0MbnkWKpbcBgdJH8n3sjT2mZaH_xREIgvlTQVQPPXx5Q1ZWk67Z15bnyjbDCfUBWui9rAs7NJV00Znal0xpT320ldjla-qRxOCB7LP_eaAtchitxvwx6m3BuxwT_3rqclv835Pd_Vor0AuQ4dpWqVVVAa9Ejid0bfhk5-A1kzwIYaI9HLtZSwmKuu9Uakm9PJhn2krLPci0Y_nQIkBfsyss9-CxcSbVo_TwWT-67OHKgD\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>sthomas@profoundmedical.com<\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5BfN2_CsXxN4HHJ-TiBToxmHrH2vRoKWQmTgdq0cYhMl_6mpIFd2T7MozP1_79iOix9h8fx-vOQVUBeyAPADkMp2ixL53Y7Sgk5gCTcY-cdgPPGnexpSZx9yPPb32B8qFPM0dwCCaTTP02BNbvj8kq0174aTPvcMtw1L92gg1gu1WFXwwWupqPbp-2dilZxhHDGmKT_ciykYggF3mho4TbnAlRfhtgqAaqOtXJp1hIykljNnApvKqVinfONgbqCYOn9ehSVTNpL4WSBeO8xgHg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><br \/><\/a>T: 619.540.9195<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTUwZmE3OWUtZTg0OC00MjBhLTkyZGItMTJkMDJlNjVhNzYzLTEwMzAxMTktMjAyNS0wOS0yMy1lbg==\/tiny\/Profound-Medical-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>New program delivers TULSA Procedure\u2019s precision treatment &#8211; minimal side effects, no overnight hospital stay \u2013 to Medicare patients across Texas TORONTO, Sept. 23, 2025 (GLOBE NEWSWIRE) &#8212; Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (\u201cProfound\u201d or the \u201cCompany\u201d), a commercial-stage medical device company developing AI-powered, incision-free therapies for ablating diseased tissue, announced today the launch of [&#8230;]\n","protected":false},"author":1,"featured_media":72320,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-72319","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment\" \/>\n<meta property=\"og:description\" content=\"New program delivers TULSA Procedure\u2019s precision treatment &#8211; minimal side effects, no overnight hospital stay \u2013 to Medicare patients across\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T12:01:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/09\/Profound-Medical-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment\",\"datePublished\":\"2025-09-23T12:01:47+00:00\",\"dateModified\":\"2025-09-23T12:01:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/\"},\"wordCount\":1213,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/\",\"name\":\"Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2025-09-23T12:01:47+00:00\",\"dateModified\":\"2025-09-23T12:01:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment","og_description":"New program delivers TULSA Procedure\u2019s precision treatment &#8211; minimal side effects, no overnight hospital stay \u2013 to Medicare patients across","og_url":"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2025-09-23T12:01:47+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/09\/Profound-Medical-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment","datePublished":"2025-09-23T12:01:47+00:00","dateModified":"2025-09-23T12:01:47+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/"},"wordCount":1213,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/","url":"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/","name":"Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2025-09-23T12:01:47+00:00","dateModified":"2025-09-23T12:01:47+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/texas-prostate-and-dallas-medical-center-launch-first-of-its-kind-tulsa-program-expanding-access-to-advanced-prostate-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/72319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=72319"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/72319\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/72320"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=72319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=72319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=72319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}